Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages

Megan L. Heinrich, Matthew L. Boisen, Diana K.S. Nelson, Duane J. Bush, Robert W. Cross, Anatoliy P. Koval, Andrew R. Hoffmann, Brandon J. Beddingfield, Kathryn M. Hastie, Megan M. Rowland, Irina Aimukanova, Sophia Koval, Raju Lathigra, Viktoriya Borisevich, Mambu Momoh, John Demby Sandi, Augustine Goba, lkponmwosa Odia, Francis Baimba, John O. AiyepadaBenevolence Ebo, Philomena Eromon, Chinedu Ugwu, Onikepe Folarin, Testimony Olumade, MacDonald D.N. Onyechi, Johnson Etafo, Rashidat Adeyemi, Elijah E. Ella, Maryam Aminu, Simji S. Gomerep, Matthew Afam Eke, Olusola Ogunsanya, George O. Akpede, Danny O. Asogun, Sylvanus A. Okogbenin, Peter O. Okokhere, Johan Holst, Jeffrey G. Shaffer, John S. Schieffelin, Thomas W. Geisbert, Erica Ollmann Saphire, Christian T. Happi, Donald S. Grant, Robert F. Garry, Luis M. Branco

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Lassa virus (LASV) is the causative agent of Lassa fever, an often-fatal hemorrhagic disease that is endemic in West Africa. Seven genetically distinct LASV lineages have been identified. As part of CEPI’s (Coalition for Epidemic Preparedness Innovations) Lassa vaccine development program, we assessed the potential of the human immune system to mount cross-reactive and cross-protective humoral immune responses to antigens from the most prevalent LASV lineages, which are lineages II and III in Nigeria and lineage IV in Sierra Leone. IgG and IgM present in the blood of Lassa fever survivors from Nigeria or Sierra Leone exhibited substantial cross-reactivity for binding to LASV nucleoprotein and two engineered (linked and prefusion) versions of the glycoproteins (GP) of lineages II–IV. There was less cross-reactivity for the Zinc protein. Serum or plasma from Nigerian Lassa fever survivors neutralized LASV pseudoviruses expressing lineage II GP better than they neutralized lineage III or IV GP expressing pseudoviruses. Sierra Leonean survivors did not exhibit a lineage bias. Neutralization titres determined using LASV pseudovirus assays showed significant correlation with titres determined by plaque reduction with infectious LASV. These studies provide guidance for comparison of humoral immunity to LASV of distinct lineages following natural infection or immunization.

Original languageEnglish (US)
Article number16030
JournalScientific reports
Issue number1
StatePublished - Dec 1 2020
Externally publishedYes

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages'. Together they form a unique fingerprint.

Cite this